Br, Rb, Zn, Fe, Se and K in Blood of Colorectal Patients by INAA and PIXE

Shenberg, C.; Feldstein, H.; Cornelis, Rita; Mees, L.; Versieck, Jacques; Vanballenberghe, L; Cafmeyer, Jan; Maenhaut, Willy

doi:10.1016/s0946-672x(11)80024-6

Cited by 23 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distribution of trace element levels in various organs indicates a significant differentiation between normal and malignant tissue, which is in good agreement with several previous findings [23]. It is well that malignant cells differ biochemically in many ways from normal cells.…”

Section: Discussionsupporting

confidence: 92%

Untitled

et al. 2005

View full text Add to dashboard Cite

Combined effect of vanadium and beta-carotene on rat liver DNA-chain break and Proton induced X-ray emission (PIXE) analysis was studied during a necrogenic dose (200 mg/kg of body weight) of Diethyl Nitrosamine (DENA) induced rat liver carcinogenesis. Morphological and histopathological changes were observed as an end point biomarker. Supplementation of vanadium (0.5 ppm ad libitum) in drinking water and beta-carotene in the basal diet (120 mg/Kg of body weight) were performed four weeks before DENA treatment and continued till the end of the experiment (16 weeks). PIXE analysis revealed the restoration of near normal value of zinc, copper, and iron, which were substantially altered when compared to carcinogen treated groups. Supplementation of both vanadium and beta-carotene four weeks before DENA injection was found to offer significant (64.73%, P < 0.001) protection against generation of single-strand breaks when compared with the carcinogen control counter parts. A significant stabilization of hepatic architecture of the cells was observed as compared to carcinogen control in vanadium plus betacarotene treated group. This study thus suggests that vanadium, a prooxidant but potential therapeutic agent yield safe and effective pharmacological formulation with beta-carotene, an antioxidant, in the inhibition of experimental rat hepatocarcinogenesis.

show abstract

Section: Discussionsupporting

confidence: 92%

Untitled

et al. 2005

View full text Add to dashboard Cite

show abstract

“…7,8 Multiple cross-sectional and case-control studies have also demonstrated an inverse association between plasma or toenail selenium levels and the risk of colon cancer and colorectal adenomatous polyps, the precursor lesion for colon cancer. [9][10][11][12][13][14][15][16][17][18] Clark et al 19 showed that among men undergoing CS for the first time, higher selenium status was inversely associated with a lower colorectal adenoma prevalence. In addition, subjects with a selenium status below a median of 128 ng/ml were more likely to have more adenomas and more likely to have adenomas located in the proximal colon.…”

Section: Discussionmentioning

confidence: 99%

Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial

Reid

Duffield-Lillico

Sunga

et al. 2005

Intl Journal of Cancer

161

154

View full text Add to dashboard Cite

Selenium status has been inversely associated with colorectal cancers (CRC) and adenomas. This investigation evaluates the association between selenium supplementation and prevalent and incident colorectal adenomas and CRC detected during the Nutritional Prevention of Cancer trial follow-up. Of the 1,312 randomized to 200 mcg of selenized yeast of matching placebo, 598 participants underwent endoscopic screening (flexible sigmoidoscopy or colonoscopy) for CRC sometime during the follow-up period, which ended in February 1, 1996. There was no colorectal screening performed at baseline. Of those screened, 77% were male (with a mean age of 62.8 years), 42% were former and 25% were current smokers. Adenomas were classified as prevalent (identified at the first endoscopic examination postrandomization during the follow-up period) or incident (identified at the second or subsequent examination). Ninety-nine prevalent and 61 incident adenomas were ascertained. Logistic regression odds ratios (OR) and 95% confidence intervals (CI) were calculated, adjusting for age, gender and smoking status. For prevalent adenomas, there was a suggestive but nonsignificant decrease in risk associated with selenium treatment (OR 5 0.67, 95% CI 5 0.43-1.05). Subjects in the lowest tertile of baseline selenium (OR 5 0.27, 95% CI 5 0.09-0.77) and current smokers (OR 5 0.27, 95% CI 5 0.11-0.66) had significant reductions in risk. The OR for incident adenomas was 0.98 (95% CI 5 0.57-1.68). In addition to being associated with a reduced risk of incident CRC, selenium supplementation was associated with a significantly reduced risk of prevalent adenomas, but only among subjects with either a low baseline selenium level or among current smokers. ' 2005 Wiley-Liss, Inc.Key words: selenium; colorectal cancer; colorectal adenomas The Nutritional Prevention of Cancer (NPC) study 1 was a placebo-controlled, randomized clinical trial designed to prevent the recurrence of nonmelanoma skin cancer (NMSC) in men and women living in the low soil selenium areas of the Eastern Coastal plain of the US. The results indicated that selenium led to a significant increase in the recurrence of squamous cell carcinoma of the skin.2 The secondary endpoints of the trial (total cancer mortality, total cancer incidence, prostate, colon and lung cancer incidence), defined in 1993, were found to be inversely associated with selenium supplementation, with the greatest reduction in risk seen among subjects in the lower third of the distribution of baseline plasma selenium levels. 1,3,4 Since the trial began, patients were interviewed at each clinical visit for new illnesses, tests and new medications. These reports included cancer screening procedures and newly diagnosed colorectal polyps, cancers and other gastrointestinal conditions. Starting in 1989, specific questions were added to the clinical interview on general cancer screening practices and exam results, focusing on breast, cervical, colorectal and prostate cancers. Patients were asked repeatedly about their perso...

show abstract

“…Trace element serum concentration is also in¯uenced by the nutritional status of patients and by the stage of a given disease (Underwood, 1977;Hambidge, 1987). A decrease in the serum concentration of selenium and zinc as well as an increase in serum levels of copper has also been described in cancer (Ma & Jiang, 1993;Shenberg et al, 1995). The effects of chemotherapy on the metabolism of essential trace elements has been studied (Pezonaga et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

“…Also, selenium has been demonstrated to be cancer protective, at least in animal models (Nelson et al, 1996). A signi®cant decrease in selenium and zinc serum levels, as well as increase in copper serum concentration, has been shown in cancer patients (Burk, 1986;Gibson, 1994;Ma & Jiang, 1993;Shenberg et al, 1995). The relationship between these alterations and the disease course (Block, 1993) andaor the nutritional status of cancer patients has been investigated (Diplock, 1993).…”

Section: Introductionmentioning

confidence: 99%

Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract

Federico¹,

Iodice

Federico

et al. 2001

Eur J Clin Nutr

View full text Add to dashboard Cite

Objective: To evaluate the effect of oral administration of selenium and zinc tablets in patients with cancer of the digestive tract during chemotherapy. Design: A case ± control, randomized study. Setting: Medical Oncology, II University of Naples, Naples, Italy. Subjects: A total of 60 patients (median age 55 y, range 46 ± 61 y) with diagnosis of gut cancer were randomized in 1999. Patients were treated for 60 days with chemotherapy. Interventions: Trace elements were measured by atomic absorption spectroscopy. The nutritional status of the patients was assessed by biochemical and bio-impedance analysis (BIA) parameters in basal condition and after 60 days of treatment. Oral administration of selenium and zinc in oral tablet form for 50 days was Se 200 mgaday (50 mgatablet) and Zn 21 mgaday (7 mgatablet). Results: Both in the basal condition and at 60 days all patients were malnourished. Selenium and zinc concentrations were signi®cantly lower (P`0.01) whereas copper concentration was signi®cantly higher (P`0.01) in cancer patients than in control subjects. However, 21a30 (70%) of those treated with Se and Zn did not showed a further worsening of nutritional status and experienced a signi®cant decrease of asthenia with an increase of appetite. On the other hand, 24a30 (80%) untreated patients had a signi®cant decline of all parameters studied after 60 days (prealbumin, cholesterol, transferrin, P`0.05 vs 0 time; total proteins, albuminaglobulin ratio, P`0.01 vs 0 time; fat-free mass, fat mass, Na aK ratio, body mass index P`0.05 vs 0 time; fat free massafat mass, total body water, extra cellularaintra cellular water, basal metabolic rate: P`0.01 vs 0 time). Conclusions: Data indicate that Se and Zn supplementation may improve the clinical course of general conditions in patients with gut cancer. These effects of Se and Zn require con®rmation in an independent trial of appropriate design before new public health recommendations regarding Se and Zn supplementation can be made.

show abstract

Br, Rb, Zn, Fe, Se and K in Blood of Colorectal Patients by INAA and PIXE

Cited by 23 publications

References 13 publications

Untitled

Untitled

Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial

Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract

Contact Info

Product

Resources

About